EGFR and neoplasm: FBXW7 loss-of-function produces complex, context-dependent effects: it can promote tumor aggressiveness by stabilizing oncogenic substrates (e.g., Cyclin E, EGFR) yet also generate pharmacologically exploitable vulnerabilities.